Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial.
Okada S, Morimoto T, Ogawa H, Sakuma M, Matsumoto C, Soejima H, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, Saito Y; JPAD Trial Investigators. Okada S, et al. Among authors: nakayama m. Diabetes Care. 2018 Aug;41(8):1757-1764. doi: 10.2337/dc18-0368. Epub 2018 Jun 16. Diabetes Care. 2018. PMID: 29909377 Clinical Trial.
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Saito Y, et al. Among authors: nakayama m. Diabetes Care. 2011 Feb;34(2):280-5. doi: 10.2337/dc10-1615. Diabetes Care. 2011. PMID: 21270185 Free PMC article. Clinical Trial.
Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial.
Okada S, Morimoto T, Ogawa H, Kanauchi M, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sakuma M, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Okada S, et al. Among authors: nakayama m. Diabetes Care. 2011 Jun;34(6):1277-83. doi: 10.2337/dc10-2451. Epub 2011 Apr 22. Diabetes Care. 2011. PMID: 21515838 Free PMC article. Clinical Trial.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, Morimoto T; JPAD Trial Investigators. Saito Y, et al. Among authors: nakayama m. Circulation. 2017 Feb 14;135(7):659-670. doi: 10.1161/CIRCULATIONAHA.116.025760. Epub 2016 Nov 15. Circulation. 2017. PMID: 27881565 Clinical Trial.
Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial.
Matsumoto C, Ogawa H, Saito Y, Okada S, Soejima H, Sakuma M, Masuda I, Nakayama M, Doi N, Jinnouchi H, Waki M, Morimoto T; JPAD Trial Investigators; JPAD Trial Investigators:. Matsumoto C, et al. Among authors: nakayama m. Diabetes Care. 2020 Feb;43(2):314-320. doi: 10.2337/dc19-1188. Epub 2019 Dec 4. Diabetes Care. 2020. PMID: 31801787 Clinical Trial.
Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus.
Matsumoto C, Ogawa H, Saito Y, Okada S, Soejima H, Sakuma M, Masuda I, Nakayama M, Doi N, Jinnouchi H, Waki M, Morimoto T. Matsumoto C, et al. Among authors: nakayama m. BMJ Open Diabetes Res Care. 2022 Mar;10(2):e002745. doi: 10.1136/bmjdrc-2021-002745. BMJ Open Diabetes Res Care. 2022. PMID: 35361621 Free PMC article. Clinical Trial.
Aspirin for primary prevention of atherosclerotic disease in Japan.
Morimoto T, Nakayama M, Saito Y, Ogawa H. Morimoto T, et al. Among authors: nakayama m. J Atheroscler Thromb. 2007 Aug;14(4):159-66. doi: 10.5551/jat.e482. Epub 2007 Aug 29. J Atheroscler Thromb. 2007. PMID: 17726295 Free article. Review.
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Ogawa H, et al. Among authors: nakayama m. JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9. JAMA. 2008. PMID: 18997198 Clinical Trial.
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Uemura S, Kanauchi M, Doi N, Sakuma M, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators. Soejima H, et al. Among authors: nakayama m. Circ J. 2012;76(6):1526-32. doi: 10.1253/circj.cj-11-1033. Epub 2012 Mar 23. Circ J. 2012. PMID: 22447019 Free article. Clinical Trial.
Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Sakuma M, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators. Soejima H, et al. Among authors: nakayama m. J Cardiol. 2013 Sep;62(3):165-70. doi: 10.1016/j.jjcc.2013.03.015. Epub 2013 Jun 16. J Cardiol. 2013. PMID: 23778008 Free article. Clinical Trial.
3,255 results